1. EXECUTIVE SUMMARY
2. MARKET SNAPSHOT
2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation
3. BUSINESS LANDSCAPE
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter’s Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations
4. TECHNOLOGICAL OUTLOOK
5. SHORT BOWEL SYNDROME MARKET BY DRUG CLASS
5.1. Introduction
5.2. Glucagon-like Peptide-2 (GLP2)
5.3. Growth Hormone
5.4. Glutamine
5.5. Others
6. SHORT BOWEL SYNDROME MARKET BY DISTRIBUTION CHANNEL
6.1. Introduction
6.2. Hospital Pharmacies
6.3. Retail Pharmacies
6.4. Online Sales
7. SHORT BOWEL SYNDROME MARKET BY GEOGRAPHY
7.1. Introduction
7.2. North America
7.2.1. USA
7.2.2. Canada
7.2.3. Mexico
7.3. South America
7.3.1. Brazil
7.3.2. Argentina
7.3.3. Others
7.4. Europe
7.4.1. Germany
7.4.2. France
7.4.3. United Kingdom
7.4.4. Spain
7.4.5. Others
7.5. Middle East and Africa
7.5.1. Saudi Arabia
7.5.2. UAE
7.5.3. Others
7.6. Asia Pacific
7.6.1. China
7.6.2. India
7.6.3. Japan
7.6.4. South Korea
7.6.5. Indonesia
7.6.6. Thailand
7.6.7. Others
8. COMPETITIVE ENVIRONMENT AND ANALYSIS
8.1. Major Players and Strategy Analysis
8.2. Market Share Analysis
8.3. Mergers, Acquisitions, Agreements, and Collaborations
8.4. Competitive Dashboard
9. COMPANY PROFILES
9.1. Takeda Pharmaceutical Company
9.2. OxThera Inc.
9.3. VectivBio AG
9.4. Merck KGaA
9.5. Ardelyx
9.6. Zealand Pharma
9.7. Nestle Health Science
9.8. Hanmi Pharm.Co., Ltd
10. APPENDIX
10.1. Currency
10.2. Assumptions
10.3. Base and Forecast Years Timeline
10.4. Key benefits for the stakeholders
10.5. Research Methodology
10.6. Abbreviations
LIST OF FIGURES
LIST OF TABLES